Lyra Therapeutics Stock Filter Stocks by Fundamentals
| LYRA Stock | USD 0.15 0.01 4.94% |
Lyra Therapeutics fundamentals help investors to digest information that contributes to Lyra Therapeutics' financial success or failures. It also enables traders to predict the movement of Lyra Stock. The fundamental analysis module provides a way to measure Lyra Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lyra Therapeutics stock.
Lyra | Shares Owned by Institutions |
Lyra Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Lyra Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lyra Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lyra Therapeutics' value.| Shares | Qube Research & Technologies | 2024-12-31 | 342.2 K | Northern Trust Corp | 2024-12-31 | 286.3 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 244.9 K | Boothbay Fund Management, Llc | 2024-12-31 | 234 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 216.5 K | Two Sigma Investments Llc | 2024-12-31 | 210 K | Jpmorgan Chase & Co | 2024-12-31 | 156.4 K | New York State Common Retirement Fund | 2024-12-31 | 154.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 111.6 K | Perceptive Advisors Llc | 2024-12-31 | 12.8 M | Blackrock Inc | 2024-12-31 | 3.1 M |
Lyra Fundamentals
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (46.73) % | ||||
| Current Valuation | 4.07 M | ||||
| Shares Outstanding | 65.88 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 50.85 % | ||||
| Number Of Shares Shorted | 2.17 M | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 6.72 X | ||||
| Revenue | 1.53 M | ||||
| Gross Profit | (42.23 M) | ||||
| EBITDA | (60.26 M) | ||||
| Net Income | (93.44 M) | ||||
| Cash And Equivalents | 120.67 M | ||||
| Cash Per Share | 3.79 X | ||||
| Total Debt | 34.38 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.40 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (70.01 M) | ||||
| Short Ratio | 2.53 X | ||||
| Earnings Per Share | (1.43) X | ||||
| Price To Earnings To Growth | 1.61 X | ||||
| Target Price | 1.25 | ||||
| Number Of Employees | 30 | ||||
| Beta | -0.18 | ||||
| Market Capitalization | 10.3 M | ||||
| Total Asset | 66.35 M | ||||
| Retained Earnings | (404.79 M) | ||||
| Working Capital | 30.39 M | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 4.82 M | ||||
| Net Asset | 66.35 M |
About Lyra Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lyra Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyra Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyra Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Lyra Therapeutics Piotroski F Score and Lyra Therapeutics Altman Z Score analysis. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share | Quarterly Revenue Growth 0.432 | Return On Assets | Return On Equity |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.